Syndicated Content about Biotechnology, Pharmaceutical and Healthcare

00:25 EDT 8th July 2015 | BioPortfolio

Latest global life science, pharmaceutical and healthcare news syndicated from over 50 publishers. 

Showing News Articles 1–25 of 230,000+

Wednesday 8th July 2015

Reproductive endocrinology: Are intramuscular testosterone injections harmful?

Injectable testosterone esters and transdermal testosterone gels have generally been assumed to be equally safe and effective forms of testosterone-replacement therapy for male hypogonadism. Now, findings from a recent study suggest that transdermal ...

Pregnancy: Fetal signalling initiates parturition

Diabetes: DNA methylation affects T2DM risk

Lipids: Xenograft model of lipid metabolism

Tuesday 7th July 2015

India IT outsourcing firms seek booster shot from Obamacare

* Obamacare to drive revenue growth as global tech spending falls

'Vampires' keep doctors in the dark for fear of stereotyping: study

SALMON, Idaho (Reuters) - It is not easy being a vampire, and even harder to come out of the coffin to a physician or therapist for fear they will misinterpret the habit of ingesting the blood of willing donors or succumb to stereotyping, a study fin...

Thromboembolic events troublesome for Lilly lung cancer drug

Lilly is seeking the FDA's blessing to market necitumumab in combination with gemcitabine and cisplatin for use in first-line treatment of patients with locally advanced or metastatic squamous NSCLC.

Allegiant Reports June 2015 Traffic

LAS VEGAS, July 07, 2015 (GLOBE NEWSWIRE) -- Allegiant Travel Company (NASDAQ:ALGT) today reported preliminary passenger traffic results for June 2015.  Scheduled Service  

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Celladon Corporation and Certain Officers – CLDN

NEW YORK, July 07, 2015 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Celladon Corporation (“Celladon” or the “Company”) (NASDAQ:CLDN) and certain of its officers.   The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities who purchased Cell...

BioClinica acquires patient recruitment, retention firm MediciGroup

Specialty trials services and tech provider BioClinica has acquired the patient recruitment and retention firm, MediciGroup. Financial terms of the deal were not disclosed. 

Revised 21st Century Cures bill takes a step back on NIH research transparency

With a House floor vote looming this week, legislators will decide on a revised bill that has decreased the amount of funding that will go to the NIH from the original bill, and removed a section that would have required NIH grant recipients to share scientific data.

Weathering the Storm With JELD-WEN's Impact-Resistant Windows and Doors

CHARLOTTE, NC -- (Marketwired) -- 07/07/15 -- Severe weather can cause major damage to a home, sometimes with little warning. With the start of hurricane season this month, residents in Florida, t...

Allergan migraine portfolio grows with Merck CGRP antagonists

Allergan will have four migraine therapies in its portfolio after licensing two oral CGRP antagonists for treatment and prevention of the debilitating headaches from Merck & Co, joining a field crowded with injectable CGRP-targeting biologics.

Payers expected to embrace Novartis heart failure drug Entresto

Specifically the drug – a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker – is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients wit...

Humana, Aetna set termination fees for deal

(Reuters) - Health insurer Humana Inc and buyer Aetna Inc set fees to be paid in the event of a failure of the largest deal in the health insurance industry.

Can Depomed get more value out of Horizon offer?

Depomed is willing to bet it on its recent launch of pain drug Nucynta, rather than take Horizon Pharma at its current offer of $29.25 per share. The specialty pharma thinks there is more value in going it alone, but they might be passing up a solid....

Indoor tanning rates dropping

(Reuters Health) - Use of indoor tanning is on the decline, according to a new study from the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute.

Rock Health: Nearly one-third of H1 digital health investors were first timers

Of the 330 investors that allocated funding to digital health companies in the first quarter, just under one third or 108 were new to the sector.

JAMA admits numerous errors in report on healthcare data breaches

A research letter about healthcare data breaches, published in the Journal of the American Medical Association in April, contained numerous errors, the authors and the publication admitted, though none apparently affected the study's conclusions.

Novartis wins early U.S. approval for major new heart drug

(Reuters) - Novartis AG on Tuesday won U.S. approval for its keenly awaited new heart failure drug Entresto earlier than expected, boosting hopes for a medicine tipped by analysts to reap billions of dollars in annual sales.

UPDATE 2-Novartis wins early U.S. approval for major new heart drug

* Consensus forecasts point to sales of $4.4 bln in 2020 (Adds byline, details on price, side effects)

UPDATE 1-Initial Ebola test on Liberia dog carcass negative -sources

* Health sources say test results inconclusive (Adds two new cases confirmed)

Novartis' heart failure drug gets speedy US approval

Novartis' heart failure drug gets speedy US approval

The health effects of green space: then and now

A sexually dimorphic hypothalamic response to chronic high-fat diet consumption